Huvepharma introduces cattle pinkeye vaccine
Infectious bovine keratoconjunctivitis is blamed for $150 million in annual losses.
Huvepharma has released a conditionally licensed vaccine formulated to prevent what The Merck Veterinary Manual describes as the “most common ocular disease of cattle.”
The vaccine, Moraxella Bovoculi Bacterin, blocks infectious bovine keratoconjunctivitis, or pinkeye caused by the bacterium Moraxella bovoculi.
Pinkeye costs the cattle industry more than $150 million a year, said Sean O’Hare, executive vice president of AgriLabs, a Huvepharma company. Permanent blindness can occur in the worst cases.
“Controlling pinkeye has always been a top concern for cattle producers,” O’Hare said.
The new vaccine “provides superior protection with eight specific isolates and an easily syringeable adjuvant,” Huvepharma stated.
“Pairing this bacterin with AgriLabs’ well-known vaccine, I-Site XP, for the prevention of pinkeye caused by M. bovis, veterinarians will expand cattle raisers prevention protocol for optimal coverage of this disease,” the Peachtree City, Georgia, company added.